Publication:
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

Loading...
Thumbnail Image

Date

2021-07-01

Authors

Sarabia De Ardanaz, Luis
Andreu-Ubero, Jose M.
Navidad-Fuentes, Miriam
Ferrer-González, Miguel Ángel
Ruíz Del Valle, Victor
Salcedo-Bellido, Inmaculada
Barrios-Rodríguez, Rocío
Cáliz-Cáliz, Rafael
Requena, Pilar

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Frontiers Research Foundation
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23-5.64), age (HR 1.05; 95% CI 1.02-1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00-1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p = 0.013), troponin I (p = 0.013), C-reactive protein (p = 0.013), neutrophils (p = 0.024), and fewer platelets (p = 0.013) and lymphocytes (p = 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters.

Description

MeSH Terms

Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
Medical Subject Headings::Phenomena and Processes::Physical Phenomena::Time::Time Factors
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization::Patient Discharge
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals
Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Platelet Count

DeCS Terms

CIE Terms

Keywords

COVID-19, Immunosupression, Tocilizumab, Mortality, Risk factor, Platelet, Mortalidad, Factores de riesgo, Plaquetas

Citation

Sarabia-De Ardanaz L, Andreu-Ubero JM, Navidad-Fuentes M, Ferrer-González MA, Ruíz-Del Valle V, et al. Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment. Front Pharmacol. 2021;12:620187.